Diabetes Meds Show Varied Associations With Liver Protection
A recent meta-analysis examined the effects of various diabetes medications on liver health in over 7 million patients with type 2 diabetes. Thiazolidinediones were found to significantly reduce the risk of hepatocellular carcinoma, while GLP-1 receptor agonists were most effective in preventing cirrhosis decompensation. SGLT2 inhibitors showed the best results in preventing progression to cirrhosis and liver-related deaths.
- ▪The analysis included 46 observational studies involving over 7 million adults with type 2 diabetes.
- ▪Thiazolidinediones were associated with a lower incidence of hepatocellular carcinoma compared to other medications.
- ▪GLP-1 receptor agonists ranked highest for reducing the risk of cirrhosis decompensation.
- ▪SGLT2 inhibitors were most effective in preventing progression to cirrhosis and liver-related deaths.
- ▪Insulin was linked to the worst outcomes for both hepatocellular carcinoma and cirrhosis decompensation.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In a network meta-analysis of 46 observational studies involving more than 7 million patients with type 2 diabetes (T2D), the use of thiazolidinediones was most strongly associated with a reduced risk for hepatocellular carcinoma (HCC). The use of GLP-1 receptor agonists (GLP-1 RAs) showed the strongest association with the reduced risk for decompensation of cirrhosis, whereas the use of SGLT2 inhibitors was most strongly associated with protection against progression to cirrhosis.METHODOLOGY:T2D has been recognized as a key cardiometabolic risk factor contributing to liver disease; however, the comparative effects of different antidiabetic drug classes on major adverse liver outcomes remain unclear.Researchers conducted a systematic review and network meta-analysis to compare the…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
